Should Congress amend Section 101?

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Should Congress amend Section 101?

A year on the from the Alice decision, many IP practitioners feel that Section 101 is in a state of ruin. Speakers at the BIO International Convention put forward proposals for Congress to overhaul the much-maligned section

The Supreme Court’s rulings in Mayo, Myriad, Alice and others have left IP practitioners exasperated at how Section 101 is now interpreted by courts and the USPTO.

At the BIO International Convention in Philadelphia last week, David Kappos, partner at Cravath Swaine & Moore, described the situation around 101 as a “state of chaos”, and outlined concerns that investment would not flow to the life science industry as a result.

Also speaking at the convention, former Chief Judge of the Federal Circuit Paul Michel said: “The 101 test is not scientific; it is not rational; it is not systematic. So once you go down the road of accepting the idea that we can have this gut feel test for eligibility or anything else, you are upon the road to doom.”

In response, people are beginning to talk about amending 101. The AIPLA and CPIP have both discussed proposals. Kristin Neuman of MPEG LA and Konstantin Linnik of Nutter McClennen & Fish also noted at the BIO convention that the 101TT group had been founded as a think tank to address the issue, with 16 members from pharma, biotech, molecular DX, BioAg, and BIO. They urged attendees to send them ideas for proposals.

Kappos said this was all positive, but emphasised that the move to amend 101 should be industry agnostic, rather than biotech specific.

“This fix-101 initiative needs to be broad based and cross industry,” he said. “It needs to be about American industry per se not just one industry. The key will be putting life sciences, which are being hurt by it, along with technology, which is also being hurt by it.”

For those that need a refresher, 101 states: “Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.”

Linnik noted that the problem lays more with the Supreme Court’s interpretation of 101, rather than the wording of 101. “So one suggestion was that 101 should just say what it says and add ‘and we mean it!” at the end,” he said.

He gave some other examples of published ideas for amending 101:

  • Amending 101 to expressly take out novelty and non-obviousness parts of 101 analysis.

Deleting 101 or renumbering to 999 to give more weight to 102, 103 and 112 and to change the order of patentability determinations.

  • Reworking other sections at play:

  •             - 100 definitions – “new and useful process, machine, manufacture, or composition of matter”, “law of nature”, “natural product:”, “abstract idea”.

                - 282 presumption of validity, defences – presumption of “patent-eligibility”; claim to be assessed as a whole.

    Others have suggested harmonizing with European regulations, though Linnik conceded this was unlikely.

    Some of these proposals were included in a February blog post by Robert Sachs of Fenwick & West on the widely-read Bilski Blog that listed “22 Ways Congress Can Save Section 101”.

    Bob Armitage, former general counsel at Eli Lilly, outlined a proposal for overhauling 101 at the convention. The conclusions from proposal this were:

    ‘Inventions” to be defined co-extensively with the Constitution’s definition of power to Congress to enact patent laws.

  • A new section 102 analysis will confirm information content or its presentation, untied to functioning, cannot be the basis for novelty – and codifies the rubric “that which infringes if later, anticipates if earlier”.

  • Section 112 claiming standards are tightened: Has the claim been expressed in terms of a product or a process, defined by its constituent structures or materials or, if a process, its (non-mental) acts? Has it been limited so as not to preempt a law, a principle or other relationship itself?

  • Valid patents are constrained to disclosed structures, materials and acts (and their equivalents) and/to functionally defined “established categories”.

  • Patents rights will never preempt use of the basic tools of science.

  • Armitage conceded that it would take a long time to change 101.

    “The best thing I can say today is that we are at the very early stages looking at what can be done,” he said. “The problem is urgent enough that we don’t have 10 years. Hopefully, we can work across these groups and come up with one proposal – although we are probably several hundred drafts away from that one proposal!”

    more from across site and SHARED ros bottom lb

    More from across our site

    A settlement between Philips and Transsion and a loss for AstraZeneca in the UK were also among the top talking points
    Working with Harvey and Microsoft, the firm has been at the forefront of developing AI tools for its lawyers, and is now exploring new projects and business models
    The Emotional Perception AI case, which centres on the patentability of an artificial neural network, will be heard next week
    Developments included a court order related to InterDigital’s anti-anti-suit injunction against Disney, and clarification on recoverable costs
    Partners at Foley Hoag examine how recent CJEU jurisprudence may serve as a catalyst for recalibrating US judicial reluctance to entertain foreign patent claims
    International law firms have high hopes for their IP practices in Saudi Arabia, with many opening offices, but recruiting and retaining talent in the Kingdom presents unique challenges
    Patrick Ogola joins us for our ‘Five minutes with’ series to discuss helping African entrepreneurs on the global stage, and explains why young lawyers should speak up
    Heli Pihlajamaa, the EPO’s principal director for patent law and procedures, joins us to take stock of the unitary patent following its second anniversary
    Kelly Thompson, chair of South African firm Adams & Adams, discusses self-belief, self-doubt, and the importance of saying yes
    The renowned food brands were represented by a host of lawyers, including members of the firms’ IP teams
    Gift this article